Literature DB >> 10026442

Pancreatic exocrine insufficiency following pancreatic resection.

P Ghaneh1, J P Neoptolemos.   

Abstract

Major pancreatic resection can cause pancreatic enzyme insufficiency with fat malabsorption, resulting in symptoms of abdominal pain, steatorrhoea and weight loss which can be extremely debilitating. The most important factors influencing subsequent development of steatorrhoea are the extent and type of surgical resection and the underlying disease process. The resultant steatorrhoea can be marked and difficult to control. There have been relatively few randomised controlled studies which have addressed this particular problem in patients who have had pancreatectomy. The use of effective doses of pancreatic enzyme supplements is essential in those patients who are symptomatic. When stabilised on therapeutically effective doses of pancreatic enzyme supplements, however, over 30% of patients still have evidence of significant levels of steatorrhoea. These results emphasise that the complete eradication of steatorrhoea is still not feasible at the present time, even using the best currently available agents, highlighting the need for further effective therapies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10026442     DOI: 10.1159/000051464

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  3 in total

1.  Assessment of Exocrine Function of Pancreas Following Pancreaticoduodenectomy.

Authors:  Kiran Thogari; Mallika Tewari; S K Shukla; S P Mishra; H S Shukla
Journal:  Indian J Surg Oncol       Date:  2019-03-18

Review 2.  Exocrine pancreatic insufficiency in adults: a shared position statement of the Italian Association for the Study of the Pancreas.

Authors:  Raffaele Pezzilli; Angelo Andriulli; Claudio Bassi; Gianpaolo Balzano; Maurizio Cantore; Gianfranco Delle Fave; Massimo Falconi
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

3.  Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension.

Authors:  C M Seiler; J Izbicki; L Varga-Szabó; L Czakó; J Fiók; C Sperti; M M Lerch; R Pezzilli; G Vasileva; A Pap; M Varga; H Friess
Journal:  Aliment Pharmacol Ther       Date:  2013-02-05       Impact factor: 8.171

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.